Investor's Business Daily on MSN
China biotech lights up. US stocks prepare for a new powerhouse.
U.S.-based biotech stocks are closely watching the China's rapid advance into the biotech field. Will they withstand the ...
Four drug companies — Agomab Therapeutics, Eikon Therapeutics, Spyglass Pharma, and Veradermics — went public this week, ...
China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the industry—and Washington—are rethinking the risks.
The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...
Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...
Across all industries, the total number of companies on track to go public could make this week the most active for IPOs ...
Feb 4 (Reuters) - Biotech firm PrimeGen US will go public in the United States through a $1.5 billion deal with blank-check ...
Department of Economic & Community Development Commissioner Daniel O'Keefe speaks at the BioCT legislative breakfast in New ...
This board strengthens Serpin Pharma’s ability to advance innovative immune‑modulating therapeutics and expand our ...
For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...
The companies Aktis Oncology, Alumis, and Parabilis Medicines bagged the biggest biotech funding rounds overall in January ...
DermCeutical EDLTM is a topical bioactive ingredient that Debut claims delivers skin-tightening benefits.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results